29326
document
Xuezhikang , an extract of cholestin , decreases plasma inflammatory markers and endothelin-1 , improve exercise-induced ischemia and subjective feelings in patients with cardiac syndrome X . Previous studies have demonstrated that Xuezhikang , an extract of cholestin , available from Chinese red yeast rice , could effectively modify lipid profile . The present study was undertaken to investigate whether Xuezhikang could modify endothelin-1 ( ET-1 ) , interleukin-6 ( IL-6 ) , high-sensitivity C-reactive protein ( CRP ) and exercise-induced ischemia in patients with cardiac syndrome X ( CSX ) . Thirty-six patients with CSX were randomly assigned to 1200 mg/d of Xuezhikang or placebo group ( n=18 respectively ) . Blood samples were drawn at day 0 and day 90 for measuring above parameters . The treadmill exercise tests and subjective feelings were also assessed at day 0 and day 90 . The data showed that Xuezhikang therapy resulted in significant reductions in total cholesterol ( TC , 19 % ) , low-density lipoprotein cholesterol ( LDL-C ) ( 26 % ) , and triglycerides ( TG ) compared with baseline ( 16 % , p < 0.01 respectively ) . The data also showed that Xuezhikang led significantly to reductions in median and log-CRP levels ( 38 % and 44 % , p < 0.01 respectively ) , IL-6 ( 20 % , p < 0.01 ) , and ET-1 ( 47 % , p < 0.01 ) compared with baseline . The exercise duration , and time to 1 mm ST-segment depression was significantly prolonged after Xuezhikang therapy ( 9 % and 6 % , p < 0.05 respectively ) accompanied by improvement of subjective feelings . Data suggested that the benefit of Xuezhikang resulted in significant modification vascular function by reduction of ET-1 , inflammatory markers and LDL cholesterol , which may be clinically important for patients with CSX .
29327
Intervention_Pharmacological
Xuezhikang
29328
Intervention_Pharmacological
Xuezhikang
29329
Intervention_Pharmacological
Xuezhikang
29330
Intervention_Pharmacological
Xuezhikang
29331
Intervention_Control
placebo
29332
Intervention_Pharmacological
Xuezhikang
29333
Intervention_Pharmacological
Xuezhikang
29334
Intervention_Pharmacological
Xuezhikang
29335
Intervention_Pharmacological
Xuezhikang
29336
Outcome_Physical
total cholesterol ( TC
29337
Outcome_Physical
low-density lipoprotein cholesterol ( LDL-C )
29338
Outcome_Physical
triglycerides ( TG )
29339
Outcome_Physical
reductions in median and log-CRP levels
29340
Outcome_Physical
IL-6
29341
Outcome_Physical
ET-1
29342
Outcome_Physical
time to 1 mm ST-segment depression
29343
Outcome_Physical
improvement of subjective feelings
29344
Outcome_Physical
vascular function
29345
Outcome_Physical
ET-1 , inflammatory markers
29346
Outcome_Physical
LDL cholesterol